AbbVie Quietly Solved Its Biggest Problem—Now What?

ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings)

AbbVie (NYSE: ABBV) isn’t what it once was, a one-trick pony dependent on Humira. Today, AbbVie is a well-diversified business with numerous blockbusters. No longer dependent on a single product or segment, the company has nimbly moved past its patent cliff and is on track to sustain growth and, more importantly, cash flow, long into the future.

The takeaway for investors is that this stock not only pays a healthy dividend, with distribution increases expected, but is also on track for higher share prices too, with the potential to advance above $300 by year’s end.

The Q2 earnings report triggered an immediate price pullback after its release, but the dip represents a buying opportunity. The pullback wasn’t due to business operations but to a planned acquisition that will dilute earnings potential this year. While the acquisition is bad news at face value, Apogee Therapeutics is a significant addition to AbbVie's Immunology portfolio with numerous blockbuster-quality candidates in late-stage trials.

Apogee's lead candidate, zumilokibart for atopic dermatitis, is estimated to be worth more than $5 billion in peak annual sales on its own, and estimates are rising. Recent trial data confirms an extended half-life, giving it a competitive advantage over the industry standard. And AbbVie's existing pipeline is already robust, with over 60 compounds and therapies in mid- to late-stage trials.

AbbVie’s Diversified Portfolio Drives Growth and Margin Strength

AbbVie had a solid Q2 with revenue of $16.99 billion, up more than 10% year-over-year and well above the consensus forecasts. Strength was driven by the Immunology and Neurosciences portfolios, which grew by 15.1% and 20.3%, respectively. Within that, blockbusters Skyrizi and Rinvoq grew by 24% each, producing a combined $7.575 billion in revenue or approximately 44.5% of the net. Oncology was the single weakness, contracting by 1.5%, while Aesthetics, which includes Botox Cosmetic, grew incrementally.

Margin news was a bright spot. The company controlled costs, benefited from improved leverage, and drove margin strength throughout the stack. The critical takeaway is that $3.65 in adjusted earnings per share is up nearly 23%, outpacing the top-line advance by more than 1,200 basis points (bps), providing ample cash flow to sustain financial health, invest in growth, and return capital to shareholders.

Guidance, the sticking point, wasn't even that bad. The biggest impact was on adjusted earnings, which were revised to a slightly lower range than previously forecast. Within that, acquisition-related costs are offset by Q2 margin strength and expected strength in upcoming quarters, leaving ABBV shares trading at bargain levels. The 18x current-year earnings at which the stock trades in early August is a discount; forward estimates deepen the discount and set the stage for significant upside over time, with moderate-to-high double-digit gains in the near-to-mid-term and triple-digit upside in the long term.

Firmly Supported, AbbVie’s Analysts Point to $300

Analyst and institutional trends suggest that AbbVie’s stock price is firmly supported, with the potential to hit $300 within the next 12 months. The Q2 results are unlikely to alter this trajectory, with sentiment remaining firm at Moderate Buy and a 76% Buy-side bias among 25 tracked analysts.

The consensus estimate offers only modest upside, but the trend counts, and it points to the $300 level. Either way, downside risk is limited, with analysts urging clients to buy, and the institutional activity echoing the sentiment. Institutions own more than 70% of the stock and have been accumulating it aggressively. The trailing 12-month pace is above $2 to $1 and holding strong in early Q3.

AbbVie’s dividend is a primary factor driving institutional ownership. The healthcare company pays a solid, reliable yield and is considered a Dividend King due to its ties to Abbott Laboratories, with a low risk to the payment outlook. The worst-case scenario is that distribution growth slows in the upcoming years. As it stands, the company runs a mid-single-digit compound annual distribution growth rate and has the capacity to sustain it for the foreseeable future.

AbbVie’s price action is favorable for investors. Post-release pullback aside, action over the past few months includes a strong rally, a break to fresh highs, and consolidation that will likely lead to a continuation. The critical support target is near the previous highs at $240, and a move below it is not anticipated.

Near-term resistance is near the existing highs. A move to fresh highs would represent a trigger for this market, suggesting a rally equalling the April to June movement will soon follow. AbbVie’s biggest risk in 2026 is execution, and it appears to be executing well, with a track record of industry-leading performance behind it.

Read this article online ›